Attachment 2 - Page 1 
$8l0-ooi* 
9007-002*-'’ 
9007-003* 
9102-004* 
910S-005* 
9105-006* 
9105-007* 
9105-008 
9105-009* 
9110-010* 
(M) 
CD 
CD 
(M) 
(M) 
(M) 
(M) 
CM) 
(M) 
CD 
HUMAN GENE TRANSFER PROTOCOLS 
I 
Rosenberg. Steven A., National Institutes of Health, Belhcsda, Maryland, The Treaonem of Paxienis with Advanced Cancer Using 
Cyclophosphamide , InierieuJdn-2 and Tumor InJiUrating Lymphocytes. 
RAC Approval: 10-3-88/NIH Approval: 3-2-89 
Minor Modification: 3-30-90 
Blaese, R. Michael, National Institutes of Health, Bethesda, Maryland; Treatment of Severe Combined Immune Deficiency (SCID) 
to Adenosine Deaminase (ADA) Deficiency with Autologous Lymphocytes Transduced with the Human ADA Gene: An Experimental 
Study 
RAC Approval: 7-31-90/NIH Approval: 9-6-90 
Major Amendment/RAC Approval: 2-10-92 
Major Amendment/NIH Approval: 4-22-92 
Minor Modification: 4-21-93 
Minor Modification: 6-7-93 
Rosenberg, Steven A., National Institutes of Health, Bethesda, Maryland; Gene Therapy of Patients with Advanced Cancer Using 
Tumor Infiltrating Lymphocytes Transduced with the Gene Coding for Tumor Secrosis Factor. 
RAC Approval: 7-31-90/NIH Approval: 9-6-90 j 
Minor Modification: 2-17-94 I 
Brenner, Malcolm IC; Mino, Joseph; Hidwitz, Craig; Santana, Victor; and Ihle, James, St. Jude Children's Research Hospital, 
Memphis, Tennessee; Autologous Bone M arrow JTransplant for Children with Acute Myelogenous Leukemia in First Complete Remission: 
Use of Marker Genes to Investigate the Biology of Marrow Recortsdtuuon and the Mechanism of Relapse. 
RAC Approval: 2-4-91/NIH Approval: 7-12-91 
Minor Modification: 11-91 
CLOSED: 1-15-93 
Brenner, Malcolm K.; Mirro, Joseph; Santana, Victor, and Ihle, James, St Jude Children’s Research Hospital, Memphis, Tennessee; 
A Phase I/U Trial of High Dose Carboplatin and Etoposide with Autologous Marrow Support for Treatment of Stage D Neuroblastoma in. 
First Remission: Use of Marker Genes to Investigate the Biology of Marrow Reconstitution and the Mecharusm of Relapse. ! 
RAC Approval 5-31-91/NIH Approval 7-12-91 
Minor Modification: 11-91 i 
CLOSED: 6-1-92 ij 
Brenner, Malcolm K-; Mino, Joseph; Santana, Victor; and Ihle, James, Sl Jude Children’s Research Hospital, Memphis, Tennessee;; 
A Phase U Trial of High-Dose Carboplatin and Etoposide with Autologous Marrow Support for Treatment of Relapse /Refractory \ 
Neuroblastoma Without Apparent Bone Marrow Involvement. i 
RAC Approval: 5-31-91/NIH Approval 7-12-91 | 
Minor Modification: 11-91 j 
CLOSED: 4-9-93 
Deisseroth, Albert B., M.D. Anderson Cancer Research Center, Houston, Texas; Autologous Bone Marrow Transplantation for 
Chronic Myelogenous Leukemia In which Retroviral Markers are Used to Discriminate between Relapse which Arises from Systerruc 
Disease Remaining after Preparative Therapy Versus Relapse due to Residual Leukemic Cells in Autologous Marrow: A Pilot Trial. 
RAC Approval: 5-31-91/NIH Approval 7-12-91 
Minor Modification; 4-19-93 jl 
CLOSED: 6-1-93 ' 
Ledley, Fred D,; Woo, Savio; Ferry, George; and Hartwell, Whigennand, Baylor College of Medicine, Houston, Texas; 
Hepatocellular Transplantation in Acute Hepatic Failure and Targeting Genetic Markers to Hepatic Cells. 
RAC Approval: 5-30-91/NlH Approval: 7-12-91 
CLOSED: Protocol Nerer Initiated 
Lotze, Michael T, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; The Administration of Interleukin-7 and 
Tumor Irfiltrating Lymphocytes to Patients with Melanoma. 
RAC Approval; 5-30-91/NIH Approval 1-17-92 
Minor Modificatioa: 11-30-92 
J 
Rosenberg, Steven A., National Institutes of Health, Bethesda, Maryland; Immunization of Ccmcer Patients Using Autologous Cancel 
Cells Modified by Insertion of the Gene for Tumor Necrosis Factor (INF). 
RAC Approval 10-7-91/NlH Approval 10-15-91 J 
Minor Modification: 7-^92 
( 374 ] 
Recombinant DNA Research, Volume 19 
